{"id":"bevacizumab-and-pemetrexed-platinum","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab is a monoclonal antibody that blocks VEGF signaling to prevent angiogenesis and starve tumors of blood supply. Pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis, and platinum agents (cisplatin or carboplatin) cause DNA crosslinking and cell death. Together, the anti-angiogenic and cytotoxic mechanisms target tumor growth through complementary pathways.","oneSentence":"This combination uses bevacizumab to inhibit tumor blood vessel formation while pemetrexed and platinum chemotherapy directly kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:08.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT07472647","phase":"PHASE1, PHASE2","title":"SYS6090 Combination Therapy in Advanced Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-02-28","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04837716","phase":"PHASE1","title":"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT01951482","phase":"PHASE3","title":"Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab","enrollment":160},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06839105","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-02-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","enrollment":214},{"nctId":"NCT04042558","phase":"PHASE2","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2019-09-26","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation","enrollment":150},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT06543069","phase":"PHASE2","title":"Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-31","conditions":"Malignant Peritoneal Mesothelioma, Advanced","enrollment":28},{"nctId":"NCT00998166","phase":"PHASE2","title":"A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-06","conditions":"Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT05284539","phase":"PHASE2","title":"Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2022-04-01","conditions":"Non Small Cell Lung Cancer","enrollment":760},{"nctId":"NCT05266846","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-05-29","conditions":"ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy","enrollment":78},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT03991403","phase":"PHASE3","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":228},{"nctId":"NCT05267366","phase":"PHASE2","title":"Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2022-02-01","conditions":"PFS, OS","enrollment":117},{"nctId":"NCT00651456","phase":"PHASE2, PHASE3","title":"Mesothelioma Avastin Plus Pemetrexed-cisplatin Study","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2008-02","conditions":"Mesothelioma","enrollment":448},{"nctId":"NCT01705184","phase":"PHASE2","title":"Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":120},{"nctId":"NCT02120807","phase":"PHASE1","title":"Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-04-15","conditions":"Stage IV Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT05675033","phase":"PHASE2","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-01-10","conditions":"Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor","enrollment":50},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT05648071","phase":"PHASE3","title":"First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-12-01","conditions":"Advanced Non-squamous Non-Small-Cell Lung Cancer","enrollment":60},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT05334277","phase":"PHASE2","title":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-06","conditions":"Non-small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05394233","phase":"PHASE2","title":"Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-06-01","conditions":"Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation","enrollment":20},{"nctId":"NCT02743923","phase":"PHASE3","title":"Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-04","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":203},{"nctId":"NCT05132413","phase":"PHASE3","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer","enrollment":561},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT00295503","phase":"PHASE2","title":"Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-02","conditions":"Mesothelioma","enrollment":53},{"nctId":"NCT04517526","phase":"PHASE2","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-11-01","conditions":"Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT","enrollment":60},{"nctId":"NCT01116219","phase":"PHASE2","title":"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-06","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT02162537","phase":"PHASE3","title":"Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain","enrollment":95},{"nctId":"NCT01351415","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06-25","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":485},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00974584","phase":"PHASE1","title":"A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-10","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":65},{"nctId":"NCT01301716","phase":"PHASE1","title":"A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-09","conditions":"Solid Cancers","enrollment":75},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259},{"nctId":"NCT00961415","phase":"PHASE3","title":"AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":376},{"nctId":"NCT01004250","phase":"PHASE2","title":"A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Non-Small Cell Lung Cancer","enrollment":109},{"nctId":"NCT01674738","phase":"PHASE2","title":"TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV","status":"WITHDRAWN","sponsor":"Aktion Bronchialkarzinom e.V.","startDate":"","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab and Pemetrexed/platinum","genericName":"Bevacizumab and Pemetrexed/platinum","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses bevacizumab to inhibit tumor blood vessel formation while pemetrexed and platinum chemotherapy directly kill cancer cells. Used for Non-small cell lung cancer (phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}